期刊
JOURNAL OF PINEAL RESEARCH
卷 48, 期 1, 页码 72-80出版社
WILEY
DOI: 10.1111/j.1600-079X.2009.00727.x
关键词
apoptosis; chemotherapy; Ewing sarcoma; melatonin
资金
- MEC [SAF2007-64726]
- FIS [PI061803, FI07-00094]
- Instituto de Salud Carlos III (ISCIII) [RD06/0020/1042]
- FICYT [BP06-161, PO02-112, COF 08-35, COF08-39]
- Minister of Science and Education (MEC)
Ewing sarcoma, the second most frequent bone cancer type, affects mainly adolescents, who have a survival of 50% 5 yr after diagnosis. Current treatments include a combination of surgery, radiotherapy and chemotherapy, which present potential serious side effects. Melatonin, a natural molecule without relevant side effects, has been previously shown to induce cytotoxicity in SK-N-MC cells, a Ewing sarcoma cell line. Here, we found that there is a synergy in the antitumor effect when melatonin (50 mu m-1 mm) is combined with vincristine at the concentration of 5-10 nm or with ifosfamide at the range of 100 mu m-1 mm. This synergism is due to the potentiation of cell death, particularly to the potentiation of apoptosis, i.e., mainly the extrinsic apoptotic pathway. There is a significant increase in the activation of caspase-3, -8, -9 and Bid when melatonin is combined with vincristine or ifosfamide compared to the individual treatments. Finally, there is also a potentiation of the early free radical production, likely dependent on the extrinsic apoptosis pathway activation, when the drugs are combined with melatonin. Other proteins which are related to this pathway including mitogen-activated protein kinase or protein kinase B/Akt are not involved in apoptosis induced by these agents separately or when combined. The results shown here together with the facts that: (i) no relevant side effects have been reported for melatonin and (ii) melatonin has a cytoprotective effect on noncancer cells, opens the door for a new approach in the treatment of the Ewing sarcoma family of tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据